ReShape Lifesciences SG&A Expenses 2015-2024 | RSLS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ReShape Lifesciences sg&a expenses from 2015 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

ReShape Lifesciences sg&a expenses from 2015 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$233.1B
Intuitive Surgical (ISRG)	$171.3B
Alcon (ALC)	$47.7B
IQVIA Holdings (IQV)	$44.2B
IDEXX Laboratories (IDXX)	$42.1B
Edwards Lifesciences (EW)	$40.7B
DexCom (DXCM)	$27.8B
STERIS (STE)	$23.5B
SONOVA HOLDING (SONVY)	$20.8B
Waters (WAT)	$19.8B
Hologic (HOLX)	$19B
Sysmex ADR (SSMXY)	$12.3B
Fresenius Medical Care AG KGaA (FMS)	$12.2B
Teleflex (TFX)	$11.4B
Globus Medical (GMED)	$9.4B
Penumbra (PEN)	$7.6B
Glaukos (GKOS)	$6.7B
Masimo (MASI)	$6.1B
TransMedics (TMDX)	$5.2B
PROCEPT BioRobotics (PRCT)	$4.3B
Integer Holdings (ITGR)	$4.3B
Tandem Diabetes Care (TNDM)	$2.8B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.6B
Inari Medical (NARI)	$2.6B
Elekta AB (EKTAY)	$2.6B
Nihon Kohden (NHNKY)	$2.5B
RxSight (RXST)	$2B
Integra LifeSciences Holdings (IART)	$1.4B
Pulse Biosciences (PLSE)	$1.2B